FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282976> ?p ?o ?g. }

• W4379282976 endingPage "e15555" @default.
• W4379282976 startingPage "e15555" @default.
• W4379282976 abstract "e15555 Background: MVASI is a biosimilar to the reference product, bevacizumab, and is the first biosimilar approved by Health Canada for the first-line (1L) treatment of metastatic colorectal cancer (mCRC). This study addresses the limited real-world evidence by describing the safety and effectiveness of MVASI as 1L therapy in mCRC. Methods: Retrospective data were collected in two waves of sites across Canada, at least 1 year (wave 1) or 2 years (wave 2) after commercial availability of MVASI at each site. Adult patients treated with ≥ 1 MVASI cycles as their 1L therapy for mCRC were included. Baseline demographic and clinical characteristics were collected 6 months prior to MVASI initiation (index date). Medical history, adjuvant treatment, and CRC diagnosis were collected within 5 years of pre-index date. Outcomes were gathered between index and chart review dates. Results: Among the 75 patients in wave 1, 36 (48.0%) were male and the median age was 62 years. Of the 164 patients in wave 2, 98 (59.8%) were male and the median age was 67 years. Most patients in wave 1 (42/69; 60.9%) and wave 2 (87/141; 61.7%) had a RAS mutation. The median time from mCRC diagnosis to MVASI initiation among wave 1 and 2 patients was 3.1 (IQR [2.1, 4.2]) and 2.3 months (IQR [1.6, 3.7]), respectively. At least one safety event of interest (EOI) was recorded for 26/75 (34.7%) wave 1 and 70/164 (42.7%) wave 2 patients (Table 1). The median progression free survival (PFS) for wave 1 and 2 patients were 9.47 and 21.38 months, respectively. Median overall survival (OS) for wave 1 patients was not estimable and was 26.45 months for wave 2 patients. Conclusions: In this real-world study, mCRC patients treated with 1L MVASI were generally representative of the Canadian mCRC population treated with 1L bevacizumab. Compared with clinical trials of MVASI and reference bevacizumab, the EOI profile and the OS data are similar, but lower rates of individual EOIs are observed in this real-world setting. The shorter PFS observed in wave 1 may be due to higher rates of comorbidities at baseline and longer time from mCRC diagnosis to index. [Table: see text]" @default.
• W4379282976 created "2023-06-05" @default.
• W4379282976 creator A5002256790 @default.
• W4379282976 creator A5005927972 @default.
• W4379282976 creator A5007198563 @default.
• W4379282976 creator A5010693870 @default.
• W4379282976 creator A5015247830 @default.
• W4379282976 creator A5023899503 @default.
• W4379282976 creator A5030188902 @default.
• W4379282976 creator A5031504642 @default.
• W4379282976 creator A5039850848 @default.
• W4379282976 creator A5043468818 @default.
• W4379282976 creator A5045291206 @default.
• W4379282976 creator A5049158373 @default.
• W4379282976 creator A5064806994 @default.
• W4379282976 creator A5067672321 @default.
• W4379282976 creator A5068852511 @default.
• W4379282976 creator A5072344941 @default.
• W4379282976 creator A5074884162 @default.
• W4379282976 creator A5084860520 @default.
• W4379282976 creator A5085687268 @default.
• W4379282976 date "2023-06-01" @default.
• W4379282976 modified "2023-09-28" @default.
• W4379282976 title "Real-world safety and effectiveness of MVASI in metastatic colorectal cancer patients in Canada." @default.
• W4379282976 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e15555" @default.
• W4379282976 hasPublicationYear "2023" @default.
• W4379282976 type Work @default.
• W4379282976 citedByCount "0" @default.
• W4379282976 crossrefType "journal-article" @default.
• W4379282976 hasAuthorship W4379282976A5002256790 @default.
• W4379282976 hasAuthorship W4379282976A5005927972 @default.
• W4379282976 hasAuthorship W4379282976A5007198563 @default.
• W4379282976 hasAuthorship W4379282976A5010693870 @default.
• W4379282976 hasAuthorship W4379282976A5015247830 @default.
• W4379282976 hasAuthorship W4379282976A5023899503 @default.
• W4379282976 hasAuthorship W4379282976A5030188902 @default.
• W4379282976 hasAuthorship W4379282976A5031504642 @default.
• W4379282976 hasAuthorship W4379282976A5039850848 @default.
• W4379282976 hasAuthorship W4379282976A5043468818 @default.
• W4379282976 hasAuthorship W4379282976A5045291206 @default.
• W4379282976 hasAuthorship W4379282976A5049158373 @default.
• W4379282976 hasAuthorship W4379282976A5064806994 @default.
• W4379282976 hasAuthorship W4379282976A5067672321 @default.
• W4379282976 hasAuthorship W4379282976A5068852511 @default.
• W4379282976 hasAuthorship W4379282976A5072344941 @default.
• W4379282976 hasAuthorship W4379282976A5074884162 @default.
• W4379282976 hasAuthorship W4379282976A5084860520 @default.
• W4379282976 hasAuthorship W4379282976A5085687268 @default.
• W4379282976 hasConcept C121608353 @default.
• W4379282976 hasConcept C126322002 @default.
• W4379282976 hasConcept C141071460 @default.
• W4379282976 hasConcept C143998085 @default.
• W4379282976 hasConcept C195910791 @default.
• W4379282976 hasConcept C197934379 @default.
• W4379282976 hasConcept C2776694085 @default.
• W4379282976 hasConcept C2777802072 @default.
• W4379282976 hasConcept C526805850 @default.
• W4379282976 hasConcept C59491497 @default.
• W4379282976 hasConcept C71924100 @default.
• W4379282976 hasConceptScore W4379282976C121608353 @default.
• W4379282976 hasConceptScore W4379282976C126322002 @default.
• W4379282976 hasConceptScore W4379282976C141071460 @default.
• W4379282976 hasConceptScore W4379282976C143998085 @default.
• W4379282976 hasConceptScore W4379282976C195910791 @default.
• W4379282976 hasConceptScore W4379282976C197934379 @default.
• W4379282976 hasConceptScore W4379282976C2776694085 @default.
• W4379282976 hasConceptScore W4379282976C2777802072 @default.
• W4379282976 hasConceptScore W4379282976C526805850 @default.
• W4379282976 hasConceptScore W4379282976C59491497 @default.
• W4379282976 hasConceptScore W4379282976C71924100 @default.
• W4379282976 hasFunder F4320307105 @default.
• W4379282976 hasIssue "16_suppl" @default.
• W4379282976 hasLocation W43792829761 @default.
• W4379282976 hasOpenAccess W4379282976 @default.
• W4379282976 hasPrimaryLocation W43792829761 @default.
• W4379282976 hasRelatedWork W1964567729 @default.
• W4379282976 hasRelatedWork W2051540233 @default.
• W4379282976 hasRelatedWork W2098707609 @default.
• W4379282976 hasRelatedWork W2122166711 @default.
• W4379282976 hasRelatedWork W2145753255 @default.
• W4379282976 hasRelatedWork W2507923170 @default.
• W4379282976 hasRelatedWork W2517493814 @default.
• W4379282976 hasRelatedWork W2588306759 @default.
• W4379282976 hasRelatedWork W3203896279 @default.
• W4379282976 hasRelatedWork W4292866350 @default.
• W4379282976 hasVolume "41" @default.
• W4379282976 isParatext "false" @default.
• W4379282976 isRetracted "false" @default.
• W4379282976 workType "article" @default.